Systemic Delivery of Adeno-Associated Viral Vectors in Mice and Dogs

  • Lakmini P. Wasala
  • Chady H. Hakim
  • Yongping Yue
  • N. Nora Yang
  • Dongsheng DuanEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1937)


Many diseases affect multiple tissues and/or organ systems, or affect tissues that are broadly distributed. For these diseases, an effective gene therapy will require systemic delivery of the therapeutic vector to all affected locations. Adeno-associated virus (AAV) has been used as a gene therapy vector for decades in preclinical studies and human trials. These studies have shown outstanding safety and efficacy of the AAV vector for gene therapy. Recent studies have revealed yet another unique feature of the AAV vector. Specifically, AAV can lead to bodywide gene transfer following a single intravascular injection. Here we describe the protocols for effective systemic delivery of AAV in both neonatal and adult mice and dogs. We also share lessons we learned from systemic gene therapy in the murine and canine models of Duchenne muscular dystrophy.

Key words

DMD Systemic delivery AAV Neonatal mice Neonatal dogs Adult mice Adult dogs 



The research on systemic AAV delivery in the Duan lab was supported by the National Institutes of Health (NS-90634, AR-70517 and AR-69085 ), Department of Defense (MD150133), Jesse’s Journey-The Foundation for Gene and Cell Therapy, Hope for Javier, Jackson Freel DMD Research Fund and Solid Biosciences Inc. The authors thank Keqing Zhang for the assistance in figure preparation.

Disclosure: D.D. is a member of the scientific advisory board, an equity holder of Solid Biosciences, LLC. D.D. is an inventor on a patent licensed to Solid Biosciences, LLC.


  1. 1.
    Russell S, Bennett J, Wellman JA et al (2017) Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390(10097):849–860. Scholar
  2. 2.
    FDA News Release (2017) FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss. Accessed 19 Dec 2017
  3. 3.
    Duan D (2016) Systemic delivery of adeno-associated viral vectors. Curr Opin Virol 21:16–25. Scholar
  4. 4.
    Mendell JR, Al-Zaidy S, Shell R et al (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377(18):1713–1722. Scholar
  5. 5.
    Gregorevic P, Blankinship MJ, Allen JM et al (2004) Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 10(8):828–834CrossRefGoogle Scholar
  6. 6.
    Yue Y, Ghosh A, Long C et al (2008) A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol Ther 16(12):1944–1952. Scholar
  7. 7.
    Yue Y, Pan X, Hakim CH et al (2015) Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus. Hum Mol Genet 24(20):5880–5890CrossRefGoogle Scholar
  8. 8.
    Bostick B, Ghosh A, Yue Y et al (2007) Systemic AAV-9 transduction in mice is influenced by animal age but not by the route of administration. Gene Ther 14(22):1605–1609CrossRefGoogle Scholar
  9. 9.
    Ghosh A, Yue Y, Long C et al (2007) Efficient whole-body transduction with trans-splicing adeno-associated viral vectors. Mol Ther 15(4):750–755. Scholar
  10. 10.
    Bostick B, Yue Y, Lai Y et al (2008) Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice. Hum Gene Ther 19(8):851–856. Scholar
  11. 11.
    Ghosh A, Yue Y, Shin J-H et al (2009) Systemic trans-splicing AAV delivery efficiently transduces the heart of adult mdx mouse, a model for Duchenne muscular dystrophy. Hum Gene Ther 20(11):1319–1328CrossRefGoogle Scholar
  12. 12.
    Yue Y, Shin JH, Duan D (2011) Whole body skeletal muscle transduction in neonatal dogs with AAV-9. Methods Mol Biol 709:313–329. Scholar
  13. 13.
    Bostick B, Shin JH, Yue Y et al (2012) AAV micro-dystrophin gene therapy alleviates stress-induced cardiac death but not myocardial fibrosis in >21-m-old mdx mice, an end-stage model of Duchenne muscular dystrophy cardiomyopathy. J Mol Cell Cardiol 53(2):217–222. S0022-2828(12)00179-4 [pii]. Scholar
  14. 14.
    Pan X, Yue Y, Zhang K et al (2013) Long-term robust myocardial transduction of the dog heart from a peripheral vein by adeno-associated virus serotype-8. Hum Gene Ther 24(6):584–594. Scholar
  15. 15.
    Hakim CH, Yue Y, Shin JH et al (2014) Systemic gene transfer reveals distinctive muscle transduction profile of tyrosine mutant AAV-1, −6, and −9 in neonatal dogs. Mol Ther Methods Clin Dev 1:14002. Scholar
  16. 16.
    Zhang Y, Yue Y, Li L et al (2013) Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy. Hum Mol Genet 22(18):3720–3729. Scholar
  17. 17.
    Pan X, Yue Y, Zhang K et al (2015) AAV-8 is more efficient than AAV-9 in transducing neonatal dog heart. Hum Gene Ther Methods 26(4):54–61CrossRefGoogle Scholar
  18. 18.
    Hakim CH, Pan X, Kodippili K et al (2016) Intravenous delivery of a novel micro-dystrophin vector prevented muscle deterioration in young adult canine Duchenne muscular dystrophy dogs. Mol Ther 24(Suppl 1):S198–S199CrossRefGoogle Scholar
  19. 19.
    Kotin RM, Snyder RO (2017) Manufacturing clinical grade recombinant adeno-associated virus using invertebrate cell lines. Hum Gene Ther 28(4):350–360. Scholar
  20. 20.
    Clement N, Grieger JC (2016) Manufacturing of recombinant adeno-associated viral vectors for clinical trials. Mol Ther Methods Clin Dev 3:16002. Scholar
  21. 21.
    Wang Z, Zhu T, Qiao C et al (2005) Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 23(3):321–328CrossRefGoogle Scholar
  22. 22.
    Zhong L, Li B, Mah CS et al (2008) Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A 105(22):7827–7832. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Lakmini P. Wasala
    • 1
  • Chady H. Hakim
    • 2
    • 3
  • Yongping Yue
    • 2
  • N. Nora Yang
    • 3
  • Dongsheng Duan
    • 1
    • 2
    • 4
    • 5
    • 6
    Email author
  1. 1.Department of Veterinary Pathobiology, College of Veterinary MedicineThe University of MissouriColumbiaUSA
  2. 2.Department of Molecular Microbiology and Immunology, School of MedicineThe University of MissouriColumbiaUSA
  3. 3.National Center for Advancing Translational Sciences, NIHRockvilleUSA
  4. 4.Department of Neurology, School of MedicineThe University of MissouriColumbiaUSA
  5. 5.Department of BioengineeringThe University of MissouriColumbiaUSA
  6. 6.Department of Biomedical Sciences, College of Veterinary MedicineThe University of MissouriColumbiaUSA

Personalised recommendations